Dosing and Administration
FREEDOM FROM DAILY DOSING
Self-injection that requires no reconstitution1
≤
1
MINUTE TO
SELF-INJECT
for most people in
the clinical trial1*
2
EVERY-
2-WEEKS
DOSING
3
CHOICES FOR
INJECTION
SITE
abdomen, thigh,
or upper arm1
- TAKHZYRO has a half-life of ~14 days; therefore, it takes ~10 weeks (ie, 6 doses) to reach steady state and ~2 weeks until 50% of TAKHZYRO leaves the body1,3
- The recommended starting dose for patients ≥12 years old is 300 mg every 2 weeks. TAKHZYRO 300 mg every 4 weeks is also effective and may be considered if the patient is well-controlled (eg, attack free) for more than 6 months1
- Remind patients to always have acute treatment on hand and to periodically check the date to ensure it hasn't expired
All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated. *In clinical studies, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds. These injection times are based on vial administration.1
DOSING AND ADMINISTRATION FOR PREVENTIVE TREATMENTS
Total doses per month for adult and adolescent patients
This presentation is not intended to compare the relative safety or efficacy of these treatments. Please refer to each product's full Prescribing Information.
TAKHZYRO1*
2
SUBCUTANEOUS
INJECTIONS
(ONE 300 MG/2ML
INJECTION EVERY 2 WEEKS)
C1 ESTERASE INHIBITOR (HUMAN)
7
INTRAVENOUS
INFUSIONS
(1000 UNITS
EVERY 3 OR 4 DAYS)
OR
SUBCUTANEOUS
INJECTIONS
(ONE INJECTION
TWICE WEEKLY;
EVERY 3 OR 4 DAYS)
ORAL PLASMA
KALLIKREIN INHIBITOR
28
CAPSULES
(ONE 150 MG CAPSULE
DAILY)
The TAKHZYRO
prefilled syringe
TAKHZYRO is available in a single-dose, ready-to-go, prefilled syringe!1 Compared to a vial, the prefilled syringe offers:
FEWER STEPS
FEWER SUPPLIES
LESS WASTE
OnePath® will work with your patients to provide at-home self-injection training and ongoing support.
What is injecting TAKHZYRO like for patients
Patients experienced with taking TAKHZYRO share their tips.
View Transcript
JACK: Injecting TAKHZYRO has not been a problem for me. For one, I only have to inject it once every two weeks. Plus, it's subcutaneous, which means it's under the skin, not in the vein. That feels manageable for me.
KELLY: Being able to switch up injection sites is a big plus for me personally, that and the fact that I can go two weeks between injections.
SORAYA: After I was trained how to do it, injecting has been manageable for me. I can do it myself, and it takes about a minute. It's an important thing I can do for myself to help reduce the frequency and severity of my HAE attacks.
SCOTT: A OnePath nurse came and showed me how to inject, and then she stayed with me, and watched me do my first injection. OnePath Product Support helped me start off right with TAKHZYRO.
DENNIS: I was having a hard time prepping the medication the way the OnePath nurse showed me. Luckily, my wife was able to do it, and I just watched her a few times. And now I am proud to say I can do it myself.
ANDREW: The actual injection takes about a minute, and then I'm free from thinking about my next dose for two weeks.
NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema, HAE, in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age. TAKHZYRO may cause serious side effects including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms, wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash and/or hives.
NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions, pain, redness and bruising, upper respiratory infection and headache. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant and breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding or plan to breastfeed.
NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.
Keep patients on track
Help your patients get the most out of treatment by talking to them about the importance of taking their medication as prescribed so they can better prevent future attacks.1
Support patients
with information on
self-administration
TAKHZYRO is intended for self-administration or administration by a caregiver after being trained by a healthcare professional.1 Inform patients and caregivers that pediatric patients (2 to less than 12 years) should not self-administer TAKHZYRO. In clinical studies, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds.1 You can use the FDA-approved Instructions For Use information below to show patients the proper way to administer TAKHZYRO. And let patients know they can refer to supplementary injection training materials to reinforce your instructions:
FDA-approved Instructions For Use
A LOWER DOSE FOR YOUNGER PATIENTS
Age-based dosing interval every 2 or 4 weeks1
Remind your patients and their caregivers to always have acute treatment on hand and periodically check the date to ensure it hasn't expired.
One month is defined as 28 days.
DOSING AND ADMINISTRATION FOR PREVENTIVE TREATMENTS
Total doses per month for pediatric patients
This presentation is not intended to compare the relative safety or efficacy of these treatments. Please refer to each product's full Prescribing Information.
AGES: 2 to <6 YEARS
options
options
AGES: 6 TO <12 YEARS
options
One month is defined as 28 days. *The recommended dosage is 150 mg administered subcutaneously every 4 weeks.1 †The recommended dosage is 150 mg administered subcutaneously every 2 weeks. A dosing interval of 150 mg every 4 weeks may be considered if the patient is well-controlled (eg, attack free) for more than 6 months.1
The TAKHZYRO
prefilled syringe
TAKHZYRO is available in a single-dose, ready-to-go, prefilled syringe!1 Compared to a vial, the prefilled syringe offers:
FEWER STEPS
FEWER SUPPLIES
LESS WASTE
OnePath® will work with your patients to provide at-home self-injection training and ongoing support.
TAKHZYRO is the only preventive treatment for HAE attacks indicated for patients as young as 2 years of age.1-4
What is injecting TAKHZYRO like for patients
Patients experienced with taking TAKHZYRO share their tips.
View Transcript
JACK: Injecting TAKHZYRO has not been a problem for me. For one, I only have to inject it once every two weeks. Plus, it's subcutaneous, which means it's under the skin, not in the vein. That feels manageable for me.
KELLY: Being able to switch up injection sites is a big plus for me personally, that and the fact that I can go two weeks between injections.
SORAYA: After I was trained how to do it, injecting has been manageable for me. I can do it myself, and it takes about a minute. It's an important thing I can do for myself to help reduce the frequency and severity of my HAE attacks.
SCOTT: A OnePath nurse came and showed me how to inject, and then she stayed with me, and watched me do my first injection. OnePath Product Support helped me start off right with TAKHZYRO.
DENNIS: I was having a hard time prepping the medication the way the OnePath nurse showed me. Luckily, my wife was able to do it, and I just watched her a few times. And now I am proud to say I can do it myself.
ANDREW: The actual injection takes about a minute, and then I'm free from thinking about my next dose for two weeks.
NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema, HAE, in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age. TAKHZYRO may cause serious side effects including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms, wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash and/or hives.
NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions, pain, redness and bruising, upper respiratory infection and headache. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant and breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding or plan to breastfeed.
NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.
Keep patients on track
Help your patients get the most out of treatment by talking to them about the importance of taking their medication as prescribed so they can better prevent future attacks.1
Support patients
with information on
self-administration
TAKHZYRO is intended for self-administration or administration by a caregiver after being trained by a healthcare professional.1 Inform patients and caregivers that pediatric patients (2 to less than 12 years) should not self-administer TAKHZYRO. In clinical studies, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds.1 You can use the FDA-approved Instructions For Use information below to show patients the proper way to administer TAKHZYRO. And let patients know they can refer to supplementary injection training materials to reinforce your instructions:
FDA-approved Instructions For Use
TAKHZYRO Quick Start Program–get patients started on TAKHZYRO
Sebastian started TAKHZYRO after learning that his frequent HAE attacks were potentially preventable.
ENROLL YOUR PATIENTS
Explore clinical safety
See safety information established in the clinical trials.
See Safety Profile